Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia

February 13, 2019 updated by: Meral Boşnak Güçlü, Gazi University

Comparison of Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children With Primary Ciliary Dyskinesia and Healthy Controls

Primary ciliary dyskinesia is an autosomal recessive disorder characterized by abnormal ciliary movement and disrupted mucociliary clearance. In uncleaned airways, microorganisms and respiratory irritants cause inflammation and infection. Permanent rhinitis and chronic sputum cough are typical features in primary ciliary dyskinesia patients. Primary ciliary dyskinesia is a disease that threatens lung function from pre-school age. One of the main causes of respiratory muscle weakness in chronic lung diseases diseases is worsening of lung function. Such a weakness causes alveolar hypoventilation, microatelectasis, reduction of the cough strength .The cough strength is important for airway cleaning.

Exercise capacity is affected in chronic lung diseases. Assessment of exercise capacity in chronic lung diseases is prognostically important. Reduced exercise capacity and pulmonary function in PCD cause decrease in physical activity level. PCD patients have low quality of life and early recognition has been found to affect the quality of life positively. Children with chronic illness have higher level of depression than healthy children.

In literature, no study investigated respiratory muscle strength, exercise capacity and physical activity PCD patients. Therefore, the investigators aimed to compare aforementioned outcomes in PCD patients and healthy controls.

Study Overview

Status

Completed

Detailed Description

According to sample size calculation 26 diagnosed primary ciliary dyskinesia patients and 26 healthy individuals will be included. Respiratory muscle strength, anaerobic and aerobic exercise capacity, physical activity, pulmonary functions, peripheral muscle strength, cough strength, respiratory muscle endurance, activity dyspnea perception, quality of life and depression will be evaluated. Primary outcome measurements are respiratory muscle strength, exercise capacity, physical activity; secondary outcomes are pulmonary functions, peripheral muscle strength, cough strength, respiratory muscle endurance, activity dyspnea perception, quality of life and depression.

Study Type

Observational

Enrollment (Actual)

26

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Yenimahalle, Turkey
        • Gazi University Faculty of Health Sciences Department of Physical Therapy and Rehabilitation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Out- patients and healthy volunteers

Description

Inclusion Criteria:

  • Diagnosed primary ciliary dyskinesia patients,
  • 6-18 years of age,
  • under standard medications,
  • stable patients without exacerbation or infection

Exclusion Criteria:

  • having cognitive disorder,
  • orthopedic or neurological disease with a potential to affect functional capacity,
  • acute infections or pneumonia,
  • problems which may prevent evaluating such as visual problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Primary ciliary dyskinesia patients
Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
Healthy individuals
Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Respiratory muscle strength
Time Frame: first day
Evaluated using mouth pressure device
first day
Functional exercise capacity
Time Frame: first day
Evaluated using 6-minute walking test
first day
Anaerobic exercise capacity
Time Frame: first day
Evaluated using 3-minute step test
first day
Physical activity
Time Frame: first day
Evaluated using a metabolic holter
first day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary functions
Time Frame: first day
Evaluated using spirometer
first day
Muscle strength
Time Frame: second day
Evaluated using hand-held dynamometer for peripheral muscles (shoulder abduction, elbow flexion, knee extension, hand grip strength)
second day
Cough strength
Time Frame: second day
Evaluated using PEFmeter
second day
Respiratory muscle endurance
Time Frame: second day]
Evaluated using respiratory muscle trainer (POWERbreathe)
second day]
Activity dyspnea
Time Frame: first day
Evaluated using Modified Borg Scale (0-10 scores, higher values represent a worse outcome)
first day
Generic Quality of life
Time Frame: second day

Cystic Fibrosis Questionnaire Revised (CFQ-R) Turkish version (Scores range from 0 to 100, with higher scores indicating better health. 9 Quality of life domains:

Physical, role/school, vitality, emotion, social, body image, eating, treatment burden, health perceptions.3 symptom scales:

Weight, respiratory, and digestion.Number of items in CFQ-R CFQ-R Teen/Adult: 50. CFQ-R Parent: 44. CFQ-R Child: 35.)

second day
Disease- specific quality of life
Time Frame: second day
Health-related quality-of-life questionnaires-Primary Ciliary Dyskinesia ( PCD-QOL) Turkish version ( PCD-QOL questionnaire developed different domains for different age groups: pediatric, adolescent, and adult patients as well as parents. These domains mainly evaluate physical, emotional, and social aspects of PCD related to QOL. Moreover, there are different domains for various symptoms at different age groups. The total numbers of items in the questionnaires are 37 in the questionnaire for children, 43 in the one for adolescents, 49 in the one for adults, 41 in the parents' questionnaire.
second day
Depression
Time Frame: second day
Children's Depression Inventory Turkish Version (Children's Depression Inventory is a 27-item, self-rated, symptom-oriented scale.
second day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Merve Fırat, Pt, Research assistant
  • Study Director: Meral Boşnak Güçlü, Pt,Phd, Associate professor
  • Principal Investigator: Tuğba Şişmanlar Eyüboğlu, MD, Medical Doctor
  • Principal Investigator: Ayşe Tana Aslan, MD,Phd, PROFESSOR

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

February 25, 2018

Study Completion (Actual)

June 30, 2018

Study Registration Dates

First Submitted

November 10, 2017

First Submitted That Met QC Criteria

December 11, 2017

First Posted (Actual)

December 12, 2017

Study Record Updates

Last Update Posted (Actual)

February 15, 2019

Last Update Submitted That Met QC Criteria

February 13, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Ciliary Dyskinesia

Subscribe